In a regulatory environment shaped by leadership turnover, evolving review practices, and policy shifts announced outside traditional channels, companies developing FDA-regulated medical products are...
Dr. Vinay Prasad, the FDA’s Chief Medical and Scientific Officer and head of the Center for Biologics Evaluation and Research (CBER), resigned abruptly on July 29
